{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003861","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.506739+00:00","generated_at":"2026-06-07T02:15:02.514053+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early","bullets":["Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.","Cash and short-term investments $66.5M as of Dec 31, 2023, including $7.9M from ATM and portion of data collaboration proceeds.","Completed enrolling and implanting patients required for FDA submission in NAUTILUS pivotal trial for idiopathic generalized epilepsy more than a quarter early.","Initial milestones achieved in first strategic data collaboration with a biotech company; expects up to $3.7M in total proceeds over nine quarters.","Project CARE pilot to expand RNS System access to community setting on track for 1H 2024 launch; centers already implanting patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003861","json":"https://secwatch.observer/filing/0001193125-24-003861.json","markdown":"https://secwatch.observer/filing/0001193125-24-003861.md","text":"https://secwatch.observer/filing/0001193125-24-003861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/d30824d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:15:02.514053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9f0eaf8f7ace1d62155ff947b15dfbda4b8f946","claim":"NeuroPace Inc reported preliminary financial results for the fiscal quarter and year ended December 31, 2023.","evidence_excerpt":"On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}